Scandion Oncology A/S will have clinical safety data for its lead compound SCO-101 presented at the European Society for Medical Oncology (ESMO) Congress 2023 taking place in Madrid on October 20-24, 2023. This will be a good opportunity for Scandion to make the safety data available to a large number of international physicians and other stakeholders. Safety data from the PANTAX phase 1b trial in patients with pancreatic cancer will be announced at a poster presentation at the congress.

This data will provide details to the topline results communicated in March 2023. The primary endpoint of the PANTAX trial was achieved as the maximum tolerated dose of SCO-101 in combination with standard of care chemotherapies gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer was established at 200 milligrams given for 6 consecutive days every 2 weeks. Scandion expects to perform a full analysis of all safety and efficacy outcomes late in 2023 with the final data to be presented in first half 2024.